The efficacy and safety of furosemide and a combination of spironolactone and hydrochlorothiazide in congestive heart failure.
The therapeutic and biochemical effects of two commonly employed diuretic preparations were compared in a double-blind fashion in 32 patients with congestive heart failure. At the doses employed, furosemide and a fixed combination of spironolactone and hydrochlothiazide maintained control of the clinical manifestations of congestive heart failure to about the same degree. However, significant biochemical changes in the renin-aldosterone system were found in patients receiving the spironolactone/thiazide combination therapy. A significant increase in plasma renin activity and a significantly greater increase in aldosterone excretion were found in the spironolactone/thiazide group compared to the furosemide group. No significant differences were observed in serum potassium levels or 24-hour potassium excretion rates in patients treated with the two diuretic preparations.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations; D004341:Drug Evaluation; D004573:Electrolytes / Q000097:blood / Q000652:urine; D005260:Female; D005665:Furosemide / Q000009:adverse effects / Q000627:therapeutic use*; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013148:Spironolactone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D004338:Drug Combinations; D004573:Electrolytes; D006852:Hydrochlorothiazide; D013148:Spironolactone; D005665:Furosemide